- Home
- SPE vs ONCY Comparison
SPE vs ONCY Comparison
Compare SPE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPE | ONCY |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.1M | 113.4M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | SPE | ONCY |
|---|---|---|
| Price | $13.54 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 33.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.14 | $0.77 |
| 52 Week High | $15.99 | $1.51 |
Technical Indicators
Market Signals| Indicator | SPE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 48.75 |
| Support Level | $13.51 | $0.90 |
| Resistance Level | $14.18 | $1.06 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 47.47 | 44.73 |
Price Performance
Historical ComparisonAbout SPE Special Opportunities Fund Inc
Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.